Neutrophil:lymphocyte ratio correlates with the uremic toxin indoxyl sulfate and predicts the risk of death in patients on hemodialysis.


Journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402

Informations de publication

Date de publication:
23 11 2022
Historique:
received: 21 07 2021
pubmed: 12 2 2022
medline: 25 11 2022
entrez: 11 2 2022
Statut: ppublish

Résumé

Chronic kidney disease (CKD) is a major public health issue associated with increased cardiovascular, infectious and all-cause mortality. The neutrophil:lymphocyte ratio (NLR) is a predictive marker of the risk of death and cardiovascular events. Uremic toxins, notably indoxyl sulfate (IS), are involved in immune deficiency and cardiovascular complications associated with CKD. The aim of this study was to assess whether the NLR was related to uremic toxins and could predict clinical outcome in hemodialysis (HD) patients. We conducted a prospective cohort study of 183 patients on chronic HD. The main objective was to study the correlation between the NLR and uremic toxin serum levels. The secondary objective was to test if the NLR can predict the incidence of mortality, cardiovascular events and infectious events. Patients were separated into two groups according to the NLR median value (3.49). The NLR at inclusion was correlated with the NLR at the 6-month (r = 0.55, P < 0.0001) and 12-month (r = 0.62, P < 0.0001) follow-up. Among uremic toxins, IS levels were higher in the group with high NLR (104 µmol/L versus 81 µmol/L; P = 0.004). In multivariate analysis, the NLR remained correlated with IS (P = 0.03). The incidence of death, cardiovascular events and severe infectious events was higher in the group with high NLR [respectively, 38% versus 18% (P = 0.004), 45% versus 26% (P = 0.01) and 33% versus 21% (P = 0.02)] than in the low NLR group. Multivariate analysis showed an independent association of the NLR with mortality (P = 0.02) and cardiovascular events (P = 0.03) but not with severe infectious events. In HD patients, the NLR predicted mortality and cardiovascular events but not severe infections and correlated positively with the level of the uremic toxin IS. The NLR could be an interesting marker for monitoring the risk of clinical events in CKD patients.

Sections du résumé

BACKGROUND
Chronic kidney disease (CKD) is a major public health issue associated with increased cardiovascular, infectious and all-cause mortality. The neutrophil:lymphocyte ratio (NLR) is a predictive marker of the risk of death and cardiovascular events. Uremic toxins, notably indoxyl sulfate (IS), are involved in immune deficiency and cardiovascular complications associated with CKD. The aim of this study was to assess whether the NLR was related to uremic toxins and could predict clinical outcome in hemodialysis (HD) patients.
METHODS
We conducted a prospective cohort study of 183 patients on chronic HD. The main objective was to study the correlation between the NLR and uremic toxin serum levels. The secondary objective was to test if the NLR can predict the incidence of mortality, cardiovascular events and infectious events.
RESULTS
Patients were separated into two groups according to the NLR median value (3.49). The NLR at inclusion was correlated with the NLR at the 6-month (r = 0.55, P < 0.0001) and 12-month (r = 0.62, P < 0.0001) follow-up. Among uremic toxins, IS levels were higher in the group with high NLR (104 µmol/L versus 81 µmol/L; P = 0.004). In multivariate analysis, the NLR remained correlated with IS (P = 0.03). The incidence of death, cardiovascular events and severe infectious events was higher in the group with high NLR [respectively, 38% versus 18% (P = 0.004), 45% versus 26% (P = 0.01) and 33% versus 21% (P = 0.02)] than in the low NLR group. Multivariate analysis showed an independent association of the NLR with mortality (P = 0.02) and cardiovascular events (P = 0.03) but not with severe infectious events.
CONCLUSIONS
In HD patients, the NLR predicted mortality and cardiovascular events but not severe infections and correlated positively with the level of the uremic toxin IS. The NLR could be an interesting marker for monitoring the risk of clinical events in CKD patients.

Identifiants

pubmed: 35146525
pii: 6526681
doi: 10.1093/ndt/gfab350
doi:

Substances chimiques

Indican N187WK1Y1J
Uremic Toxins 0
Toxins, Biological 0
Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2528-2537

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.

Auteurs

Guillaume Lano (G)

Aix Marseille Université, INSERM, INRAE, C2VN, Marseille, France.
Centre de néphrologie et transplantation rénale, Hôpital de la conception AP-HM, Marseille, France.

Marion Sallée (M)

Aix Marseille Université, INSERM, INRAE, C2VN, Marseille, France.
Centre de néphrologie et transplantation rénale, Hôpital de la conception AP-HM, Marseille, France.

Marion Pelletier (M)

Centre de néphrologie et transplantation rénale, Hôpital de la conception AP-HM, Marseille, France.

Stanislas Bataille (S)

Aix Marseille Université, INSERM, INRAE, C2VN, Marseille, France.
Elsan, Phocean Institute of Nephrology, Clinique Bouchard, Marseille, France.

Megan Fraisse (M)

Aix Marseille Université, INSERM, INRAE, C2VN, Marseille, France.

Nathalie McKay (N)

Aix Marseille Université, INSERM, INRAE, C2VN, Marseille, France.

Philippe Brunet (P)

Aix Marseille Université, INSERM, INRAE, C2VN, Marseille, France.
Centre de néphrologie et transplantation rénale, Hôpital de la conception AP-HM, Marseille, France.

Laetitia Dou (L)

Aix Marseille Université, INSERM, INRAE, C2VN, Marseille, France.

Stéphane Burtey (S)

Aix Marseille Université, INSERM, INRAE, C2VN, Marseille, France.
Centre de néphrologie et transplantation rénale, Hôpital de la conception AP-HM, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH